-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 L01aQLLbnEPBAA76neRpTYXLiigBFI+X+t1Wt/HROIx/Thm4a+ilCIq36K0KUyUW
 Xb6khB7/ctUB6iU8yNPV1Q==

<SEC-DOCUMENT>0000950123-09-013386.txt : 20090611
<SEC-HEADER>0000950123-09-013386.hdr.sgml : 20090611
<ACCEPTANCE-DATETIME>20090611172709
ACCESSION NUMBER:		0000950123-09-013386
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090611
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090611
DATE AS OF CHANGE:		20090611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		09887709

	BUSINESS ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111
		BUSINESS PHONE:		720-488-1711

	MAIL ADDRESS:	
		STREET 1:		6400 SOUTH FIDDLER
		STREET 2:		SUITE 1750
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c86746e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): June 11, 2009 (June 9, 2009)</B>



<P style="font-size: 24pt" align="center"><B>Lifevantage
Corporation<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Colorado</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-30489</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>90-0224471</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>11545 W. Bernardo Court,
Suite 301, San Diego, California <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>92127</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(858) 312-8000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.</B>

<P style="font-size: 10pt" align="left">On June&nbsp;11, 2009, Lifevantage
Corporation (the &#8220;Company&#8221;) announced that the Board of Directors
of the Company has appointed Carrie E. Carlander as Chief Financial Officer of
the Company effective June&nbsp;9, 2009. The press release announcing the
appointment is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein
by reference.

<P style="font-size: 10pt" align="left">Ms.&nbsp;Carlander most recently served
as Chief Financial Officer of Genelux Corporation. Prior to Genelux,
Ms.&nbsp;Carlander served as Chief Financial Officer for Adventrx
Pharmaceuticals. She has also served in the role of Vice President Finance for
V-Enable, Inc. and Websense Inc. Ms.&nbsp;Carlander has an MBA in Finance and
Management from San Diego State University, a Bachelor&#8217;s Degree from the
University of California at San Diego and is a Certified Management Accountant.
Ms.&nbsp;Carlander will be entitled to an annual base salary of $200,000.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure.</B>

<P style="font-size: 10pt" align="left">On June&nbsp;11, 2009, the Company
issued a press release entitled &#8220;Carrie Carlander Joins LifeVantage as
Chief Financial Officer.&#8221; The press release is attached as
Exhibit&nbsp;99.1 hereto.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits

<P style="font-size: 10pt" align="left">Exhibit&nbsp;99.1 Press Release, dated
June&nbsp;11, 2009, entitled &#8220;Carrie Carlander Joins LifeVantage as Chief
Financial Officer.&#8221;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<P style="font-size: 10pt" align="left">Date: June&nbsp;11, 2009

<P style="font-size: 10pt; margin-left: 45%" align="left">LIFEVANTAGE
CORPORATION

<P style="font-size: 10pt; margin-left: 45%" align="left">By:
<U>/s/&nbsp;Bradford K. Amman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Bradford K. Amman<BR>
Secretary/Treasurer<BR>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release, dated June&nbsp;11, 2009, entitled &#147;Carrie Carlander Joins LifeVantage as Chief Financial Officer.&#148;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c86746exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&nbsp;
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>FOR IMMEDIATE RELEASE</B><BR>
June&nbsp;11, 2009
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>NEWS</B><BR>
OTCBB: LFVN</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Contact:</B></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>Jan Strode<br>
(619)&nbsp;890-4040<br>
Jean Golden<br>
(612)&nbsp;385-2324</B></DIV></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Carrie Carlander Joins LifeVantage as Chief Financial Officer</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">SAN DIEGO, CA, June&nbsp;11, 2009 &#151; <u>LifeVantage Corporation (OTCBB: LFVN),</u> maker of Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, today
announced the Board of Directors has approved the appointment of Carrie Carlander as Chief
Financial Officer.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Ms.&nbsp;Carlander most recently served as Chief Financial Officer of Genelux Corporation. Prior to
Genelux, Ms.&nbsp;Carlander served as Chief Financial Officer for Adventrx Pharmaceuticals. She has also
served in the role of Vice President Finance for V-Enable, Inc. and Websense Inc. Ms.&nbsp;Carlander has
an MBA in Finance and Management from San Diego State University, a Bachelor&#146;s Degree from the
University of California at San Diego and is a Certified Management Accountant.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;I am very pleased that Carrie has joined LifeVantage,&#148; said David W. Brown, President and CEO of
LifeVantage Corporation. &#147; Her impressive background and track record with dynamic public companies
and her proven abilities in corporate governance, strategic planning, investor relations, and
finance, will be a tremendous asset to LifeVantage.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;I am excited and honored to join the LifeVantage team, as I feel this is a company with
tremendous growth potential. I look forward to joining David and the rest of the management team
in building upon the great momentum the Company has recently generated through its launch into the
network marketing channel and its rapid attraction of thousands of independent distributors,&#148; said
Ms.&nbsp;Carlander.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">-More-
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><u>LifeVantage Corporation</u></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products
company, dedicated to helping people reach their health and wellness goals through science-based
solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops
nutraceutical products, including <u><B>Protandim</B></u><SUP style="font-size: 85%; vertical-align: text-top"><B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></B></SUP><B>, </B>that leverage the company&#146;s expertise and
that are intended to deliver significant health benefits to consumers. For more information, visit
<u><B>www.LifeVantage.com</B></u><B>.</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The Company uses the words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;could,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;plan,&#148;
&#147;target&#148; and similar terms and phrases, including references to assumptions, to identify
forward-looking statements. These forward-looking statements are based on the Company&#146;s current
expectations and beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be
materially different from those anticipated and discussed herein. These risks and uncertainties
include, among others, the risk that government regulators and regulations could adversely affect
our business; future laws or regulations may hinder or prohibit the production or sale of our
existing product and any future products; unfavorable publicity could materially hurt our business;
and the Company&#146;s ability to protect our intellectual property rights and the value of our product.
These and other risk factors are discussed in greater detail in the Company&#146;s Annual Report on
Form&nbsp;10-KSB under the caption &#147;Risk Factors&#148;, and in other documents filed the Company from time to
time with the Securities and Exchange Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by law.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Note to Editors: Contact Jan Strode at 619-890-4040 or Jean Golden 612-385-2324 for interviews,
photography, and other requests.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
